ClinicalTrials.gg

Program

JNJ-98768111

A development code.

Its studies are mostly in Prostatic Neoplasms, led by Johnson & Johnson.

Furthest: phase 1, since Jul 31, 20261 company-led study, 1 open or runningNext primary completion: Mar 16, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson11 open or runningphase 1since Jul 31, 2026Jul 31, 2026Mar 16, 2029phase 1 · NCT07746713
  • Named in Johnson & Johnson’s own pipeline as JNJ-8111, phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 31, 2026First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT07746713 · 160 planned · United States, Israel

Ahead

  1. Mar 16, 2029Primary completion: phase 1 study in Prostatic NeoplasmsNCT07746713

TargetBeta

“A Phase 1 Trial of JNJ-98768111, an Antibody Drug Conjugate (ADC) Targeting Human Kallikrein-2 (KLK2) for Advanced Prostate Cancer”study text, read by Claude · the study

Other programs on KLK2

ProgramCompanyFurthest phaseStudies
pasritamigJohnson & Johnsonphase 35

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07746713Prostatic Neoplasms · United States, Israel1RecruitingMar 16, 2029160

How it is read

Names in the registry

  • “JNJ-98768111”, 1 entry

Codes read as this program: JNJ98768111.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.